{"id":358835,"date":"2025-09-03T14:00:53","date_gmt":"2025-09-03T08:30:53","guid":{"rendered":"https:\/\/www.scconline.com\/blog\/?p=358835"},"modified":"2025-09-03T14:05:10","modified_gmt":"2025-09-03T08:35:10","slug":"medical-and-pharmaceutical-marketing-practices-amendment-ucmpmd-ucpmp-2025-medical-reforms","status":"publish","type":"post","link":"https:\/\/www.scconline.com\/blog\/post\/2025\/09\/03\/medical-and-pharmaceutical-marketing-practices-amendment-ucmpmd-ucpmp-2025-medical-reforms\/","title":{"rendered":"2025 Amendments to Medical and Pharmaceutical Marketing Practices: Valuation of Free Samples &amp; Annual Disclosures"},"content":{"rendered":"<div style=\"text-align: justify; line-height: 150%;\">\n<p style=\"\">On 1-9-2025, the <span style=\"font-weight: bold;\">Ministry of Chemicals and Fertilizers<\/span> issued Amendments to:<\/p>\n<ul style=\"list-style-type: disc;\">\n<li>\n<p><span style=\"font-weight: bold;\">Uniform Code for Pharmaceuticals Marketing Practices (&#8216;UCPMC&#8217;) 2024<\/span>.<\/p>\n<\/li>\n<li>\n<p style=\"margin-bottom: 3%; font-weight: bold;\">Uniform Code for Marketing Practices in Medical Devices (&#8216;UCMPMD&#8217;) 2024.<\/p>\n<\/li>\n<\/ul>\n<p style=\"margin-bottom: 3%;\">These Amendments simplify disclosure of marketing expenditure and sample valuation by shifting reporting from government portals to industry associations, aimed at enhancing transparency, accountability, and ethical conduct in the pharmaceutical sector.<\/p>\n<h3>Background:<\/h3>\n<p style=\"font-weight: bold;\">UCPMP 2024<\/p>\n<p style=\"margin-bottom: 3%;\">Originally introduced in 2014 as a voluntary framework, the Uniform Code for Pharmaceuticals Marketing Practices was revised in 2024 to include semi-mandatory provisions, annual disclosure requirements, and a formal complaint redressal system to curb unethical promotional practices in the pharmaceutical sector.<a id=\"fnref1\" href=\"#fn1\" title=\"1. Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024 - reg | Department of Pharmaceuticals\"><sup>1<\/sup><\/a><\/p>\n<p style=\"font-weight: bold;\">UCMPMD 2024<\/p>\n<p style=\"margin-bottom: 3%;\">Launched in September 2024, the Uniform Code for Marketing Practices in Medical Devices is India&#8217;s first dedicated code for regulating device marketing. It establishes standards for sample valuation, expenditure disclosure, and industry-led compliance, aiming to enhance transparency and ethical conduct across the medical device ecosystem.<a id=\"fnref2\" href=\"#fn2\" title=\"2. HYPERLINK &ldquo;https:\/\/pharma-dept.gov.in\/policy\/uniform-code-marketing-practices-medical-devices-ucmpmd-2024 &ldquo;Uniform Code for Marketing Practices in Medical Devices (UCMPMD) 2024 | Department of Pharmaceuticals\"><sup>2<\/sup><\/a><\/p>\n<h3>Key Amendments to UCMPMD 2024:<\/h3>\n<p>The 2025 amendment to the <span style=\"font-weight: bold;\">UCMPMD<\/span> aims to make things easier for <span style=\"font-weight: bold;\">medical device companies<\/span> while ensuring they follow ethical marketing practices in pharmaceutical marketing.<\/p>\n<ol style=\"list-style-type: decimal;\">\n<li>\n<p>A new <span style=\"font-weight: bold;\">Clause 5.2.2(vi)<\/span> is inserted which establishes a standardized methodology for valuing free evaluation samples distributed to healthcare professionals, ensuring consistency and fairness in reporting marketing expenditure. It states:<\/p>\n<ul style=\"list-style-type: disc;\">\n<li>\n<p><span style=\"font-weight: bold;\">For manufacturers<\/span>: Samples will be valued on a <span style=\"font-weight: bold;\">per-unit basis<\/span> (e.g., per device, vial, or milliliter), using the price charged to the stockist or immediate customer for the same <span style=\"font-weight: bold;\">make, brand, product variant, and value<\/span> of the medical device.<\/p>\n<\/li>\n<li>\n<p><span style=\"font-weight: bold;\">For purchased samples<\/span>: The <span style=\"font-weight: bold;\">purchase price<\/span> will be used for valuation.<\/p>\n<\/li>\n<li>\n<p><span style=\"font-weight: bold;\">Annual Averaging<\/span>: In both cases, the value must be recorded as the <span style=\"font-weight: bold;\">average price<\/span> charged or paid over the financial year.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<p><span style=\"font-weight: bold;\">Clause 9.1<\/span> has been updated to replace the reference to &#8220;UCPMP&#8221; with &#8220;UCMPMD&#8221;, to align terminology with the medical device sector.<\/p>\n<\/li>\n<li>\n<p>To reduce administrative burden and promotes ease of doing business, <span style=\"font-weight: bold;\">Clause 14.3<\/span> is modified to simplifies the disclosure process for marketing expenditure:<\/p>\n<ul style=\"list-style-type: disc;\">\n<li>\n<p>Companies will be required to submit their <span style=\"font-weight: bold;\">annual declaration<\/span> within <span style=\"font-weight: bold;\">two months<\/span> of the financial year&#8217;s end.<\/p>\n<\/li>\n<li>\n<p>Disclosures can be made either:<\/p>\n<ul style=\"list-style-type: circle;\">\n<li>\n<p>On the <span style=\"font-weight: bold;\">website of the industry association<\/span> to which the company belongs, or<\/p>\n<\/li>\n<li>\n<p>On the <span style=\"font-weight: bold;\">UCMPMD portal<\/span> if the company is unaffiliated.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<p>Companies with multiple memberships can choose one association for disclosure and must notify the others. Future disclosures will continue with the selected association unless formally changed and communicated to both the Department and the original association.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<p>To ensure the integrity and accessibility of disclosed data, <span style=\"font-weight: bold;\">Clause 14.4<\/span> mandates that:<\/p>\n<ul style=\"list-style-type: disc;\">\n<li>\n<p>Associations must implement secure systems to store and protect member data.<\/p>\n<\/li>\n<li>\n<p>Data must be retained for a minimum of five years, extendable if required for investigations or legal proceedings.<\/p>\n<\/li>\n<li>\n<p>Associations must be prepared to share data with relevant authorities (Ethics Committee, Apex Committee, courts) upon request, without compromising its integrity.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<p>To further streamline compliance, following provisions are removed:<\/p>\n<ul style=\"list-style-type: disc;\">\n<li>\n<p><span style=\"font-weight: bold;\">Clause 9.5<\/span>: Requirement to upload details on the UCPMP portal.<\/p>\n<\/li>\n<li>\n<p><span style=\"font-weight: bold;\">Clause 11.10<\/span>: References to the UCPMP portal, eliminating duplication in reporting.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<p>A new Annexure is introduced which ensures disclosure of marketing expenditure, uniformity and facilitates easier audits and reviews. Key fields include:<\/p>\n<ul style=\"list-style-type: disc;\">\n<li>\n<p>Company identification (CIN, PAN, address)<\/p>\n<\/li>\n<li>\n<p>Financial year and domestic sales<\/p>\n<\/li>\n<li>\n<p>Value and quantity of free evaluation samples<\/p>\n<\/li>\n<li>\n<p>Details of educational events (direct and third-party)<\/p>\n<\/li>\n<li>\n<p>Methodology for valuation<\/p>\n<\/li>\n<li>\n<p style=\"margin-bottom: 3%;\">Digital signature of the executive head.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ol>\n<h3>Key Amendments to UCPMP 2024:<\/h3>\n<p>The 2025 amendment to the <span style=\"font-weight: bold;\">UCPMP<\/span> introduces a series of <span style=\"font-weight: bold;\">targeted reforms aimed at simplifying compliance<\/span>, enhancing transparency, and reinforcing ethical standards in pharmaceutical marketing.<\/p>\n<ol style=\"list-style-type: decimal;\">\n<li>\n<p>The newly inserted <span style=\"font-weight: bold;\">Clause 5.1(g)<\/span>, mandates that pharmaceutical companies to calculate and disclose the monetary <span style=\"font-weight: bold;\">value of free samples<\/span> distributed to healthcare practitioners <span style=\"font-weight: bold;\">using a standardized valuation method<\/span>. It states:<\/p>\n<ul style=\"list-style-type: disc;\">\n<li>\n<p><span style=\"font-weight: bold;\">If the company manufactures the samples<\/span>: The valuation will be done <span style=\"font-weight: bold;\">per unit<\/span> (e.g., per tablet, capsule, vial, gram, or milliliter). The value will be based on the <span style=\"font-weight: bold;\">price charged to the stockist or immediate customer<\/span> for the same dosage form and strength.<\/p>\n<\/li>\n<li>\n<p><span style=\"font-weight: bold;\">If the company purchases the samples from another supplier<\/span>: The valuation will be based on the <span style=\"font-weight: bold;\">purchase price<\/span> of the medicine for the same dosage form and strength.<\/p>\n<\/li>\n<li>\n<p><span style=\"font-weight: bold;\">Annual Averaging<\/span>: The price of free samples will be recorded as the <span style=\"font-weight: bold;\">average price charged or paid<\/span> over the financial year.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<p>Earlier companies were required to upload monthly marketing expenditure reports to the <span style=\"font-weight: bold;\">Department of Pharmaceuticals<\/span> (&#8216;DoP&#8217;) portal. To reduce the administrative burden and duplication, modification to <span style=\"font-weight: bold;\">Clause 14.4<\/span>, to states:<\/p>\n<ul style=\"list-style-type: disc;\">\n<li>\n<p>Companies will be required to submit a declaration within <span style=\"font-weight: bold;\">two months<\/span> of the financial year&#8217;s end.<\/p>\n<\/li>\n<li>\n<p>Submission Options:<\/p>\n<ul style=\"list-style-type: circle;\">\n<li>\n<p>To the <span style=\"font-weight: bold;\">industry association<\/span> of which the company is a member.<\/p>\n<\/li>\n<li>\n<p>If unaffiliated, disclosure will be made on the <span style=\"font-weight: bold;\">UCPMP portal<\/span>.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<p>Companies belonging to multiple associations can choose one for disclosure and notify others. Future disclosures must continue with the chosen association unless formally changed.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<p>To ensure that disclosures are not only made but are also safeguarded and accessible for accountability and recognise the sensitivity of disclosed data, the amendment to <span style=\"font-weight: bold;\">Clause 14.5<\/span> mandates:<\/p>\n<ul style=\"list-style-type: disc;\">\n<li>\n<p>Associations will implement robust systems to protect member data.<\/p>\n<\/li>\n<li>\n<p>Minimum of <span style=\"font-weight: bold;\">five years<\/span>, expandable if required for investigations or legal proceedings.<\/p>\n<\/li>\n<li>\n<p>Associations will share data with relevant authorities (Ethics Committee, Apex Committee, courts) when requested, without compromising data integrity.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<p>To further streamline compliance, following provisions are removed:<\/p>\n<ul style=\"list-style-type: disc;\">\n<li>\n<p><span style=\"font-weight: bold;\">Clause 9.5<\/span>: Requirement to upload details on the UCPMP portal.<\/p>\n<\/li>\n<li>\n<p><span style=\"font-weight: bold;\">Clause 11.10<\/span>: Reference to the DoP, eliminating duplication in reporting.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<p>The Amendment introduces a new standardized Annexure that replaces the earlier forms. The new format ensures uniformity and facilitates easier audits and reviews, key fields including:<\/p>\n<ul style=\"list-style-type: disc;\">\n<li>\n<p>Company identification (CIN, PAN, address)<\/p>\n<\/li>\n<li>\n<p>Financial year and domestic sales<\/p>\n<\/li>\n<li>\n<p>Value and quantity of free samples<\/p>\n<\/li>\n<li>\n<p>Details of educational events (direct and third-party)<\/p>\n<\/li>\n<li>\n<p>Methodology for valuation<\/p>\n<\/li>\n<li>\n<p style=\"margin-bottom: 3%;\">Digital signature of the executive head.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ol>\n<\/div>\n<hr\/>\n<p style=\"margin-left: 18pt; text-indent: -18pt;\"><a id=\"fn1\" href=\"#fnref1\">1.<\/a> <a href=\"https:\/\/pharma-dept.gov.in\/important-document\/uniform-code-pharmaceutical-marketing-practices-ucpmp-2024-reg\" target=\"_blank\">Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024 &#8211; reg | Department of Pharmaceuticals<\/a><\/p>\n<p style=\"margin-left: 18pt; text-indent: -18pt;\"><a id=\"fn2\" href=\"#fnref2\">2.<\/a> HYPERLINK &#8220;<a href=\"https:\/\/pharma-dept.gov.in\/policy\/uniform-code-marketing-practices-medical-devices-ucmpmd-2024\" target=\"_blank\">https:\/\/pharma-dept.gov.in\/policy\/uniform-code-marketing-practices-medical-devices-ucmpmd-2024<\/a> &#8220;Uniform Code for Marketing Practices in Medical Devices (UCMPMD) 2024 | Department of Pharmaceuticals<\/p>\n","protected":false},"excerpt":{"rendered":"<p style=\"font-style: italic;\">DoP revises the UCPMP&#8217;24 and UCMPMD&#8217;24 to simplify compliance procedures and reduce the administrative burden on pharmaceutical and medical device companies, particularly in relation to the disclosure of marketing expenditure involving free samples and educational programs.<\/p>\n","protected":false},"author":67525,"featured_media":358836,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[4,1193],"tags":[88502,88501,88500,88499,88503,88504,88497,88498],"class_list":["post-358835","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-legislationupdates","category-notifications","tag-compliance-update","tag-dop","tag-free-sample-disclosure","tag-marketing-code-amendment","tag-medical-device-marketing","tag-pharma-ethics","tag-ucmpmd-2024","tag-ucpmp-2024"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v26.4 (Yoast SEO v26.4) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>2025 Amendments to Medical and Pharmaceutical Marketing Practices | SCC Times<\/title>\n<meta name=\"description\" content=\"2025 Amendments to Medical and Pharmaceutical Marketing Practices: DoP revises the UCPMP\u201924 and UCMPMD\u201924 to streamline marketing expenditure reporting and clarify rules for sample valuation and educational sponsorships.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.scconline.com\/blog\/post\/2025\/09\/03\/medical-and-pharmaceutical-marketing-practices-amendment-ucmpmd-ucpmp-2025-medical-reforms\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"2025 Amendments to Medical and Pharmaceutical Marketing Practices: Valuation of Free Samples &amp; Annual Disclosures\" \/>\n<meta property=\"og:description\" content=\"2025 Amendments to Medical and Pharmaceutical Marketing Practices: DoP revises the UCPMP\u201924 and UCMPMD\u201924 to streamline marketing expenditure reporting and clarify rules for sample valuation and educational sponsorships.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.scconline.com\/blog\/post\/2025\/09\/03\/medical-and-pharmaceutical-marketing-practices-amendment-ucmpmd-ucpmp-2025-medical-reforms\/\" \/>\n<meta property=\"og:site_name\" content=\"SCC Times\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/scc.online\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-03T08:30:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-03T08:35:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2025\/09\/Medical-and-Pharmaceutical-Marketing-Practices.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"886\" \/>\n\t<meta property=\"og:image:height\" content=\"590\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Shubhi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"2025 Amendments to Medical and Pharmaceutical Marketing Practices: Valuation of Free Samples &amp; Annual Disclosures\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Shubhi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.scconline.com\/blog\/post\/2025\/09\/03\/medical-and-pharmaceutical-marketing-practices-amendment-ucmpmd-ucpmp-2025-medical-reforms\/\",\"url\":\"https:\/\/www.scconline.com\/blog\/post\/2025\/09\/03\/medical-and-pharmaceutical-marketing-practices-amendment-ucmpmd-ucpmp-2025-medical-reforms\/\",\"name\":\"2025 Amendments to Medical and Pharmaceutical Marketing Practices | SCC Times\",\"isPartOf\":{\"@id\":\"https:\/\/www.scconline.com\/blog\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.scconline.com\/blog\/post\/2025\/09\/03\/medical-and-pharmaceutical-marketing-practices-amendment-ucmpmd-ucpmp-2025-medical-reforms\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.scconline.com\/blog\/post\/2025\/09\/03\/medical-and-pharmaceutical-marketing-practices-amendment-ucmpmd-ucpmp-2025-medical-reforms\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2025\/09\/Medical-and-Pharmaceutical-Marketing-Practices.webp\",\"datePublished\":\"2025-09-03T08:30:53+00:00\",\"dateModified\":\"2025-09-03T08:35:10+00:00\",\"author\":{\"@id\":\"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/3e8a14a0016e76e01d69a7a3ca6164ac\"},\"description\":\"2025 Amendments to Medical and Pharmaceutical Marketing Practices: DoP revises the UCPMP\u201924 and UCMPMD\u201924 to streamline marketing expenditure reporting and clarify rules for sample valuation and educational sponsorships.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.scconline.com\/blog\/post\/2025\/09\/03\/medical-and-pharmaceutical-marketing-practices-amendment-ucmpmd-ucpmp-2025-medical-reforms\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.scconline.com\/blog\/post\/2025\/09\/03\/medical-and-pharmaceutical-marketing-practices-amendment-ucmpmd-ucpmp-2025-medical-reforms\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.scconline.com\/blog\/post\/2025\/09\/03\/medical-and-pharmaceutical-marketing-practices-amendment-ucmpmd-ucpmp-2025-medical-reforms\/#primaryimage\",\"url\":\"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2025\/09\/Medical-and-Pharmaceutical-Marketing-Practices.webp\",\"contentUrl\":\"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2025\/09\/Medical-and-Pharmaceutical-Marketing-Practices.webp\",\"width\":886,\"height\":590,\"caption\":\"Medical and Pharmaceutical Marketing Practices\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.scconline.com\/blog\/post\/2025\/09\/03\/medical-and-pharmaceutical-marketing-practices-amendment-ucmpmd-ucpmp-2025-medical-reforms\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.scconline.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"2025 Amendments to Medical and Pharmaceutical Marketing Practices: Valuation of Free Samples &amp; Annual Disclosures\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.scconline.com\/blog\/#website\",\"url\":\"https:\/\/www.scconline.com\/blog\/\",\"name\":\"SCC Times\",\"description\":\"Bringing you the Best Analytical Legal News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.scconline.com\/blog\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/3e8a14a0016e76e01d69a7a3ca6164ac\",\"name\":\"Shubhi\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/0da7aaea2ff41a69b9926284cf9e1f24b3f53e830b045ed1d3f853355e3e5157?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/0da7aaea2ff41a69b9926284cf9e1f24b3f53e830b045ed1d3f853355e3e5157?s=96&d=mm&r=g\",\"caption\":\"Shubhi\"},\"url\":\"https:\/\/www.scconline.com\/blog\/post\/author\/shubhi\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"2025 Amendments to Medical and Pharmaceutical Marketing Practices | SCC Times","description":"2025 Amendments to Medical and Pharmaceutical Marketing Practices: DoP revises the UCPMP\u201924 and UCMPMD\u201924 to streamline marketing expenditure reporting and clarify rules for sample valuation and educational sponsorships.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.scconline.com\/blog\/post\/2025\/09\/03\/medical-and-pharmaceutical-marketing-practices-amendment-ucmpmd-ucpmp-2025-medical-reforms\/","og_locale":"en_US","og_type":"article","og_title":"2025 Amendments to Medical and Pharmaceutical Marketing Practices: Valuation of Free Samples & Annual Disclosures","og_description":"2025 Amendments to Medical and Pharmaceutical Marketing Practices: DoP revises the UCPMP\u201924 and UCMPMD\u201924 to streamline marketing expenditure reporting and clarify rules for sample valuation and educational sponsorships.","og_url":"https:\/\/www.scconline.com\/blog\/post\/2025\/09\/03\/medical-and-pharmaceutical-marketing-practices-amendment-ucmpmd-ucpmp-2025-medical-reforms\/","og_site_name":"SCC Times","article_publisher":"https:\/\/www.facebook.com\/scc.online\/","article_published_time":"2025-09-03T08:30:53+00:00","article_modified_time":"2025-09-03T08:35:10+00:00","og_image":[{"width":886,"height":590,"url":"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2025\/09\/Medical-and-Pharmaceutical-Marketing-Practices.jpg","type":"image\/jpeg"}],"author":"Shubhi","twitter_card":"summary_large_image","twitter_title":"2025 Amendments to Medical and Pharmaceutical Marketing Practices: Valuation of Free Samples &amp; Annual Disclosures","twitter_misc":{"Written by":"Shubhi","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.scconline.com\/blog\/post\/2025\/09\/03\/medical-and-pharmaceutical-marketing-practices-amendment-ucmpmd-ucpmp-2025-medical-reforms\/","url":"https:\/\/www.scconline.com\/blog\/post\/2025\/09\/03\/medical-and-pharmaceutical-marketing-practices-amendment-ucmpmd-ucpmp-2025-medical-reforms\/","name":"2025 Amendments to Medical and Pharmaceutical Marketing Practices | SCC Times","isPartOf":{"@id":"https:\/\/www.scconline.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.scconline.com\/blog\/post\/2025\/09\/03\/medical-and-pharmaceutical-marketing-practices-amendment-ucmpmd-ucpmp-2025-medical-reforms\/#primaryimage"},"image":{"@id":"https:\/\/www.scconline.com\/blog\/post\/2025\/09\/03\/medical-and-pharmaceutical-marketing-practices-amendment-ucmpmd-ucpmp-2025-medical-reforms\/#primaryimage"},"thumbnailUrl":"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2025\/09\/Medical-and-Pharmaceutical-Marketing-Practices.webp","datePublished":"2025-09-03T08:30:53+00:00","dateModified":"2025-09-03T08:35:10+00:00","author":{"@id":"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/3e8a14a0016e76e01d69a7a3ca6164ac"},"description":"2025 Amendments to Medical and Pharmaceutical Marketing Practices: DoP revises the UCPMP\u201924 and UCMPMD\u201924 to streamline marketing expenditure reporting and clarify rules for sample valuation and educational sponsorships.","breadcrumb":{"@id":"https:\/\/www.scconline.com\/blog\/post\/2025\/09\/03\/medical-and-pharmaceutical-marketing-practices-amendment-ucmpmd-ucpmp-2025-medical-reforms\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.scconline.com\/blog\/post\/2025\/09\/03\/medical-and-pharmaceutical-marketing-practices-amendment-ucmpmd-ucpmp-2025-medical-reforms\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.scconline.com\/blog\/post\/2025\/09\/03\/medical-and-pharmaceutical-marketing-practices-amendment-ucmpmd-ucpmp-2025-medical-reforms\/#primaryimage","url":"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2025\/09\/Medical-and-Pharmaceutical-Marketing-Practices.webp","contentUrl":"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2025\/09\/Medical-and-Pharmaceutical-Marketing-Practices.webp","width":886,"height":590,"caption":"Medical and Pharmaceutical Marketing Practices"},{"@type":"BreadcrumbList","@id":"https:\/\/www.scconline.com\/blog\/post\/2025\/09\/03\/medical-and-pharmaceutical-marketing-practices-amendment-ucmpmd-ucpmp-2025-medical-reforms\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.scconline.com\/blog\/"},{"@type":"ListItem","position":2,"name":"2025 Amendments to Medical and Pharmaceutical Marketing Practices: Valuation of Free Samples &amp; Annual Disclosures"}]},{"@type":"WebSite","@id":"https:\/\/www.scconline.com\/blog\/#website","url":"https:\/\/www.scconline.com\/blog\/","name":"SCC Times","description":"Bringing you the Best Analytical Legal News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.scconline.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/3e8a14a0016e76e01d69a7a3ca6164ac","name":"Shubhi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/0da7aaea2ff41a69b9926284cf9e1f24b3f53e830b045ed1d3f853355e3e5157?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0da7aaea2ff41a69b9926284cf9e1f24b3f53e830b045ed1d3f853355e3e5157?s=96&d=mm&r=g","caption":"Shubhi"},"url":"https:\/\/www.scconline.com\/blog\/post\/author\/shubhi\/"}]}},"jetpack_featured_media_url":"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2025\/09\/Medical-and-Pharmaceutical-Marketing-Practices.webp","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":272466,"url":"https:\/\/www.scconline.com\/blog\/post\/2022\/08\/27\/the-doctor-drug-company-nexus-diagnosis-and-treatment\/","url_meta":{"origin":358835,"position":0},"title":"The Doctor &#8211; Drug Company Nexus: Diagnosis and Treatment","author":"Bhumika Indulia","date":"August 27, 2022","format":false,"excerpt":"by Murali Neelakantan\u2020 Cite as: 2022 SCC OnLine Blog Exp 64","rel":"","context":"In &quot;Experts Corner&quot;","block_context":{"text":"Experts Corner","link":"https:\/\/www.scconline.com\/blog\/post\/category\/experts_corner\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2022\/08\/MicrosoftTeams-image-13-1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2022\/08\/MicrosoftTeams-image-13-1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2022\/08\/MicrosoftTeams-image-13-1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2022\/08\/MicrosoftTeams-image-13-1.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2022\/08\/MicrosoftTeams-image-13-1.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":259549,"url":"https:\/\/www.scconline.com\/blog\/post\/2022\/01\/05\/us-california-genetic-information-privacy-act-takes-effect\/","url_meta":{"origin":358835,"position":1},"title":"US- California | Genetic Information Privacy Act comes into effect","author":"Bhumika Indulia","date":"January 5, 2022","format":false,"excerpt":"On January 01, 2022, the Senate Bill ('SB') 41 which establishes the Genetic Information Privacy Act entered into effect, following its approval by the California Governor on 6 October 2021. Applicability: The Act applies to direct-to-consumer genetic testing companies. Key Features: Direct-to-consumer genetic testing company must: Provide clear and complete\u2026","rel":"","context":"In &quot;Foreign Legislation&quot;","block_context":{"text":"Foreign Legislation","link":"https:\/\/www.scconline.com\/blog\/post\/category\/legislationupdates\/foreign\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2017\/08\/privacy.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2017\/08\/privacy.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2017\/08\/privacy.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2017\/08\/privacy.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2017\/08\/privacy.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":329217,"url":"https:\/\/www.scconline.com\/blog\/post\/2024\/08\/23\/delhi-high-court-directs-fresh-consideration-injunction-mankind-mercykind-trademark-dispute-legal-news\/","url_meta":{"origin":358835,"position":2},"title":"[Mankind v Mercykind] Delhi High Court directs fresh consideration of Injunction Application in Trademark Dispute","author":"Arunima","date":"August 23, 2024","format":false,"excerpt":"The Court was informed that during the pendency of the present appeal, the Mercykind Pharmaceuticals made significant changes both in its logo and get up of products which are being marketed by it, which would clearly merit consideration afresh by the Single Judge.","rel":"","context":"In &quot;Case Briefs&quot;","block_context":{"text":"Case Briefs","link":"https:\/\/www.scconline.com\/blog\/post\/category\/casebriefs\/"},"img":{"alt_text":"Delhi High Court","src":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2024\/02\/Delhi-High-Court.webp?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2024\/02\/Delhi-High-Court.webp?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2024\/02\/Delhi-High-Court.webp?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2024\/02\/Delhi-High-Court.webp?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":327291,"url":"https:\/\/www.scconline.com\/blog\/post\/2024\/07\/25\/need-for-uniform-civil-code-to-curb-superstitious-practices-mp-high-court-scc-times\/","url_meta":{"origin":358835,"position":3},"title":"MP High Court quashes charges under Muslim Women (Protection of Rights on Marriage) Act; stresses on need for UCC to curb superstitious practices","author":"Ritu","date":"July 25, 2024","format":false,"excerpt":"\u201cThere are a lot of other deprecating, fundamentalist, superstitious and ultra-conservative practices prevalent in the society that are clothed in the name of faith and belief.\u201d","rel":"","context":"In &quot;Case Briefs&quot;","block_context":{"text":"Case Briefs","link":"https:\/\/www.scconline.com\/blog\/post\/category\/casebriefs\/"},"img":{"alt_text":"Madhya Pradesh High Court","src":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2024\/03\/Madhya-Pradesh-High-Court.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2024\/03\/Madhya-Pradesh-High-Court.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2024\/03\/Madhya-Pradesh-High-Court.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2024\/03\/Madhya-Pradesh-High-Court.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":364551,"url":"https:\/\/www.scconline.com\/blog\/post\/2025\/10\/23\/sam-advises-tau-jb-chemicals-cci-torrent-deal\/","url_meta":{"origin":358835,"position":4},"title":"SAM &amp; Co. advises Tau Investment &amp; J. B. Chemicals in Securing Conditional CCI Nod for the Torrent-JB Chemicals Deal","author":"Editor","date":"October 23, 2025","format":false,"excerpt":"Approval covers the proposed stake purchase and subsequent amalgamation of JB Chemicals with Torrent.","rel":"","context":"In &quot;Law Firms News&quot;","block_context":{"text":"Law Firms News","link":"https:\/\/www.scconline.com\/blog\/post\/category\/news\/law-firms-news\/"},"img":{"alt_text":"SAM & Co. advises Tau Investment & J. B. Chemicals","src":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2025\/10\/SAM-Co.-advises-Tau-Investment-J.-B.-Chemicals.webp?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2025\/10\/SAM-Co.-advises-Tau-Investment-J.-B.-Chemicals.webp?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2025\/10\/SAM-Co.-advises-Tau-Investment-J.-B.-Chemicals.webp?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2025\/10\/SAM-Co.-advises-Tau-Investment-J.-B.-Chemicals.webp?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":329389,"url":"https:\/\/www.scconline.com\/blog\/post\/2024\/08\/27\/clarity-amid-complexity-navigating-sebis-disclosure-mandates-on-litigation-and-disputes\/","url_meta":{"origin":358835,"position":5},"title":"Clarity Amid Complexity: Navigating SEBI&#8217;s Disclosure Mandates on Litigation and Disputes","author":"Bhumika Indulia","date":"August 27, 2024","format":false,"excerpt":"by Ashmit Sharma\u2020","rel":"","context":"In &quot;Op Eds&quot;","block_context":{"text":"Op Eds","link":"https:\/\/www.scconline.com\/blog\/post\/category\/op-ed\/legal-analysis\/"},"img":{"alt_text":"SEBI's Disclosure Mandates","src":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2024\/08\/SEBIs-Disclosure-Mandates.webp?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2024\/08\/SEBIs-Disclosure-Mandates.webp?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2024\/08\/SEBIs-Disclosure-Mandates.webp?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2024\/08\/SEBIs-Disclosure-Mandates.webp?resize=700%2C400&ssl=1 2x"},"classes":[]}],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/posts\/358835","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/users\/67525"}],"replies":[{"embeddable":true,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/comments?post=358835"}],"version-history":[{"count":0,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/posts\/358835\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/media\/358836"}],"wp:attachment":[{"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/media?parent=358835"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/categories?post=358835"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/tags?post=358835"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}